BRM5013 Chap.5 Pluripotent Stem Cells and Reprogramming
Pluripotent Stem Cells and Reprogramming
Reprogramming shows that differentiated identity can be reset, but factor delivery is only the start of the evidence. This chapter compares integrating and non-integrating routes, molecular and functional reset, direct conversion and pluripotent intermediates, and the isogenic-control logic needed to make patient-derived disease models credible.
What this chapter covers
- 01
Nuclear transfer and reversible identity
- 02
OSKM and induced pluripotent cells
- 03
Integrating and non-integrating delivery
- 04
Epigenetic and transcriptomic reset
- 05
Patient-derived disease models
- 06
Isogenic correction and clonal effects
Worked example · free
Build an isogenic disease model
- +1Correct the variant to create a matched comparison.
- +1Differentiate patient and corrected lines under comparable conditions.
- +1Verify identity, purity and maturity before measuring phenotype.
- +1Repeat with independent lines or a reciprocal perturbation.
Key terms
- Somatic nuclear transfer
- Transfer of a differentiated-cell nucleus into an enucleated oocyte to test developmental resetting.
- Integrating delivery
- Factor delivery that can insert genetic material into the host genome.
- Isogenic comparison
- A comparison designed to differ mainly at a targeted genetic change.
Pluripotent Stem Cells and Reprogramming FAQ
What does reprogramming demonstrate?
It demonstrates that a differentiated state is actively maintained and can be reset by an appropriate regulatory environment or factor program. It does not imply that every cell converts efficiently or that the resulting line is automatically stable, complete or safe.
Why prefer a non-integrating route for a cell product?
Avoiding permanent insertion reduces one source of genomic alteration and persistent factor expression. The method must still be evaluated for efficiency, residual reagent, reproducibility, genomic stability and the quality of the differentiated product.
Does gene correction prove the variant caused the phenotype?
Correction that reverses a phenotype is strong evidence, especially in a matched background. Confidence improves when editing is verified, differentiation quality is comparable and the result is reproduced in independent clones or with a complementary perturbation. The corrected and parental lines should experience matched handling, and the relevant molecular consequence of the edit should be confirmed.
If only one clone improves, clonal selection or an unintended change remains plausible. Reciprocal introduction of the variant, independent editing reagents or another mechanistic intervention can add convergence. The claim must also remain within the differentiated cell type, assay and developmental state tested.
Correction can show that a variant contributes to a cellular phenotype without by itself explaining penetrance, whole-organism disease or clinical outcome. Those broader conclusions require additional human and physiological evidence.
Assessment move
Separate five stages on your notes: delivery, reprogramming, characterisation, differentiation and product testing. Compare routes by purpose and downstream risk. For disease models, practise the patient line, isogenic correction, matched differentiation, phenotype and replication sequence. Reject any option that treats one corrected clone as complete proof. Turn the five stages into an evidence ledger.
Under delivery, record whether the method integrates into the genome or is transient and what residual material must be checked. Under reprogramming, record loss of the starting identity and acquisition of the intended regulatory state. Under characterisation, combine morphology, markers, genome integrity and stable self-renewal with functional differentiation evidence.
No single positive marker should stand in for the whole identity claim. At differentiation, specify the target lineage, purity, maturity and unwanted populations. At product testing, use a function linked to the intended research or therapeutic use. Compare reprogramming routes by what happens downstream.
A route may be efficient but create integration risk; a transient route may reduce that concern but require repeated delivery; direct conversion may preserve age-related features while limiting expansion or breadth. State which trade-off matters for the task rather than naming one best method. For disease modelling, draw patient and control lines through matched differentiation and the same phenotype assay.
Add an isogenic correction to reduce genetic-background differences, but treat it as one piece of convergent evidence. Verify the edit, compare independent clones and ask whether an unedited workflow control experienced the same handling. A rescue is stronger when the corrected line loses the disease phenotype and an independent perturbation supports the same mechanism. Practise separating identity from safety.
Pluripotent markers and differentiation capacity do not guarantee genomic stability, absence of residual undifferentiated cells or safe behaviour after transplantation. Purity, stability, maturation and relevant functional tests belong in the answer whenever the downstream use involves a cell product. Use precise language for potency and fate.
Pluripotency describes developmental capacity, not current differentiation into every tissue; reprogramming describes an induced state change, not proof that every cell completed it. Finish each scenario by naming the narrowest supported claim and one assay that would address the leading alternative. This converts a list of techniques into a reasoned sequence from cell-state induction to verified, purpose-appropriate function.
Working through Pluripotent Stem Cells and Reprogramming in BRM5013? Sia is AskSia’s AI Biology tutor — ask any BRM5013 Pluripotent Stem Cells and Reprogramming question and get a clear, step-by-step explanation grounded in how BRM5013 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
